Laboratório S. José has been acquired by SYNLAB
The private shareholders of Laboratório S. José have sold the company to SYNLAB.
Founded over 40 years ago, Laboratório S. José is a clinical analysis laboratory based in Portugal. it offers excellence in service delivery, constantly investing in technology, qualification of human capital and enhancement of relationships with customers and partners.
SYNLAB is an international medical diagnostics provider. Present in more than 40 countries, the group's network includes more than 400 laboratories.
Oaklins' team in Portugal advised the seller in this transaction.
![](/api/deal-hero-image/105635/deal-hero-image.jpg)
![](/api/deal-party-images/105635/deal-parties.png)
Talk to the deal team
Related deals
Afric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn moreBayer AG has entered into a takeover agreement with Cara Care
Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
Learn more